Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- Robert L. Coleman
- , Mark F. Brady
- , Thomas J. Herzog
- , Paul Sabbatini
- , Deborah K. Armstrong
- , Joan L. Walker
- , Byoung Gie Kim
- , Keiichi Fujiwara
- , Krishnansu S. Tewari
- , David M. O'Malley
- , Susan A. Davidson
- , Stephen C. Rubin
- , Paul DiSilvestro
- , Karen Basen-Engquist
- , Helen Huang
- , John K. Chan
- , Nick M. Spirtos
- , Raheela Ashfaq
- , Robert S. Mannel
- University of Texas MD Anderson Cancer Center
- SUNY Buffalo
- University of Cincinnati
- Memorial Sloan-Kettering Cancer Center
- Johns Hopkins University
- University of Oklahoma
- Sungkyunkwan University
- Saitama Medical University
- University of California at Irvine
- Ohio State University
- University of Colorado Anschutz Medical Campus
- Women and Infants Hospital of Rhode Island
- Palo Alto Medical Foundation
- Women's Cancer Center of Nevada
- Miraca Life Sciences
Research output: Contribution to journal › Article › peer-review
570
Scopus
citations